Diabetes

Rybelsus is a revolutionary new oral Type 2 diabetes medication containing the active ingredient semaglutide. This innovative product from Novo Nordisk was approved by Health Canada in 2019. Unlike injectable analogues, Rybelsus comes in tablet form and does not require daily injections. The convenience of pill administration promotes better patient adherence.

Our pages are protected with SSL to keep your personal and payment data safe.

256-bit encrypted connection

View Offers

T&Cs Apply

Rybelsus® tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels.

DISCLAIMER: The Canada Pharmacy provides health and related information to assist consumers in making informed decisions about their health. The information we provide is not intended to be used for medical diagnosis or treatment, or as a substitute for professional medical advice. Patients should always consult their physician or other qualified healthcare provider prior to starting any new treatment or with any questions regarding a medical condition. The Canada Pharmacy does not recommend or endorse any specific tests, medications, procedures or opinions. Reliance on any information provided by The Canada Pharmacy is solely at your own risk.